$MRUS
Merus N.V.

2020 Q3 Form 10-Q Financial Statement

#000156459020051276 Filed on November 05, 2020

View on sec.gov

Income Statement

Concept 2020 Q3 2019 Q3
Revenue $8.570M $8.160M
YoY Change 5.02% 7.79%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $9.140M $8.020M
YoY Change 13.97% 159.55%
% of Gross Profit
Research & Development $17.54M $13.51M
YoY Change 29.83% -2.31%
% of Gross Profit
Depreciation & Amortization $380.0K $310.0K
YoY Change 22.58% 82.35%
% of Gross Profit
Operating Expenses $26.67M $21.54M
YoY Change 23.82% 3.41%
Operating Profit
YoY Change
Interest Expense -$4.790M $4.060M
YoY Change -217.98% 155.35%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$22.90M -$9.320M
YoY Change 145.71% -24.53%
Income Tax $177.0K -$54.00K
% Of Pretax Income
Net Earnings -$23.08M -$9.267M
YoY Change 149.0% -25.45%
Net Earnings / Revenue -269.25% -113.57%
Basic Earnings Per Share
Diluted Earnings Per Share -$794.2K -$396.2K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q3 2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $190.2M $171.7M
YoY Change 10.77% -23.42%
Cash & Equivalents $139.2M $134.6M
Short-Term Investments $51.00M $37.10M
Other Short-Term Assets $1.876M $6.300M
YoY Change -70.22% 23.53%
Inventory
Prepaid Expenses
Receivables $2.100M $1.800M
Other Receivables $200.0K $1.900M
Total Short-Term Assets $201.3M $181.7M
YoY Change 10.79% -22.75%
LONG-TERM ASSETS
Property, Plant & Equipment $8.000M $10.10M
YoY Change -20.79% 339.13%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00 $11.60M
YoY Change -100.0% -40.51%
Other Assets $1.400M $1.000M
YoY Change 40.0% -9.09%
Total Long-Term Assets $12.20M $25.20M
YoY Change -51.59% -1.56%
TOTAL ASSETS
Total Short-Term Assets $201.3M $181.7M
Total Long-Term Assets $12.20M $25.20M
Total Assets $213.5M $206.9M
YoY Change 3.19% -20.67%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.700M $2.700M
YoY Change 74.07% -67.47%
Accrued Expenses $19.82M $3.100M
YoY Change 539.32% -6.06%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $1.600M
YoY Change
Total Short-Term Liabilities $45.40M $32.30M
YoY Change 40.56% -27.25%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $83.60M $97.90M
YoY Change -14.61% -16.89%
Total Long-Term Liabilities $83.60M $97.90M
YoY Change -14.61% -16.89%
TOTAL LIABILITIES
Total Short-Term Liabilities $45.40M $32.30M
Total Long-Term Liabilities $83.60M $97.90M
Total Liabilities $129.0M $130.2M
YoY Change -0.92% -19.73%
SHAREHOLDERS EQUITY
Retained Earnings -$372.1M
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $84.50M $77.01M
YoY Change
Total Liabilities & Shareholders Equity $213.5M $206.9M
YoY Change 3.19% -20.67%

Cashflow Statement

Concept 2020 Q3 2019 Q3
OPERATING ACTIVITIES
Net Income -$23.08M -$9.267M
YoY Change 149.0% -25.45%
Depreciation, Depletion And Amortization $380.0K $310.0K
YoY Change 22.58% 82.35%
Cash From Operating Activities -$11.70M -$14.02M
YoY Change -16.55% -23.72%
INVESTING ACTIVITIES
Capital Expenditures -$350.0K -$1.340M
YoY Change -73.88% 139.29%
Acquisitions
YoY Change
Other Investing Activities -$5.760M $5.800M
YoY Change -199.31% -139.89%
Cash From Investing Activities -$6.110M $4.450M
YoY Change -237.3% -129.47%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 20.00K 20.00K
YoY Change 0.0% -81.82%
NET CHANGE
Cash From Operating Activities -11.70M -14.02M
Cash From Investing Activities -6.110M 4.450M
Cash From Financing Activities 20.00K 20.00K
Net Change In Cash -17.79M -9.550M
YoY Change 86.28% -71.38%
FREE CASH FLOW
Cash From Operating Activities -$11.70M -$14.02M
Capital Expenditures -$350.0K -$1.340M
Free Cash Flow -$11.35M -$12.68M
YoY Change -10.49% -28.84%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
mrus Investment Income Expense Interest
InvestmentIncomeExpenseInterest
1756000
mrus Investment Income Expense Interest
InvestmentIncomeExpenseInterest
367000
CY2019Q3 mrus Investment Income Expense Interest
InvestmentIncomeExpenseInterest
591000
CY2020Q3 mrus Investment Income Expense Interest
InvestmentIncomeExpenseInterest
-12000
CY2020Q3 us-gaap Held To Maturity Securities
HeldToMaturitySecurities
63705000
CY2019Q4 us-gaap Held To Maturity Securities
HeldToMaturitySecurities
78215000
CY2019Q3 mrus Stock Issued During Period Value Stock Options Exercised And Restricted Stock Units Vested
StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsVested
16000
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2068000
CY2019Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-3561000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-9267000
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
77005000
CY2020Q2 mrus Stock Issued During Period Value Stock Options Exercised And Restricted Stock Units Vested
StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsVested
291000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1192000
CY2020Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
2201000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-17974000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
100296000
CY2020Q3 mrus Stock Issued During Period Value Stock Options Exercised And Restricted Stock Units Vested
StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsVested
22000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2844000
CY2020Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
4414000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
84501000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-23075000
us-gaap Nature Of Operations
NatureOfOperations
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1. Overview </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Merus N.V. is a clinical-stage oncology company developing innovative antibody therapeutics, headquartered in Utrecht, the Netherlands. Merus US, Inc. is a wholly-owned subsidiary of Merus N.V. located at 139 Main Street, Cambridge, Massachusetts, United States (collectively, the “Company”).</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since inception, the Company has generated an accumulated deficit of $372.1 million as of September 30, 2020. The Company expects to continue to incur significant expenses and operating losses for the foreseeable future as its antibody candidates advance through discovery, pre-clinical development and clinical trials and as it seeks regulatory approval and pursues commercialization of any approved antibody candidate.</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result, the Company may need additional financing to support its continuing operations. Until the Company can generate significant revenue from product sales, if ever, the Company expects to finance its operations through public equity offerings, debt financings, or other sources, which may include collaborations, business development and licensing opportunities with third parties. Adequate additional financing may not be available to the Company on acceptable terms, or at all. The Company’s inability to raise capital as and when needed would have a negative impact on its financial condition and ability to pursue its business strategy. The Company will need to generate significant revenues to achieve profitability and may never do so.</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on the Company’s current operating plan, the Company expects that its existing cash and cash equivalents and marketable securities of $190.2 million as of September 30, 2020 will be sufficient to fund its operations into the second half of 2022.</p>
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-372100000
CY2020Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
190200000
CY2020Q3 us-gaap Held To Maturity Securities
HeldToMaturitySecurities
63705000
CY2019Q4 us-gaap Held To Maturity Securities
HeldToMaturitySecurities
78215000
CY2020Q3 us-gaap Held To Maturity Securities Fair Value
HeldToMaturitySecuritiesFairValue
63749000
CY2019Q4 us-gaap Held To Maturity Securities Fair Value
HeldToMaturitySecuritiesFairValue
78254000
CY2020Q3 mrus Prepaid Clinical And Manufacturing Costs Current
PrepaidClinicalAndManufacturingCostsCurrent
5085000
CY2019Q4 mrus Prepaid Clinical And Manufacturing Costs Current
PrepaidClinicalAndManufacturingCostsCurrent
2779000
CY2020Q3 mrus Prepaid General And Administrative Expenses
PrepaidGeneralAndAdministrativeExpenses
1862000
CY2019Q4 mrus Prepaid General And Administrative Expenses
PrepaidGeneralAndAdministrativeExpenses
789000
CY2020Q3 us-gaap Interest Receivable Current
InterestReceivableCurrent
187000
CY2019Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
259000
CY2020Q3 us-gaap Other Assets Current
OtherAssetsCurrent
1876000
CY2019Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1124000
CY2020Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
9010000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4951000
CY2020Q3 mrus Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
14021000
CY2019Q4 mrus Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
6618000
CY2020Q3 mrus Accrued General And Administrative Expenses
AccruedGeneralAndAdministrativeExpenses
2877000
CY2019Q4 mrus Accrued General And Administrative Expenses
AccruedGeneralAndAdministrativeExpenses
2402000
CY2020Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2905000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4495000
CY2020Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
16000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
21000
CY2020Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
19819000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
13536000
CY2020Q3 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
126000
CY2019Q3 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
47000
us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
164000
us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
145000
CY2020Q3 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
131000
CY2019Q3 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
-48000
us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
143000
us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
-11000
CY2020Q3 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
257000
CY2019Q3 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
-1000
us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
307000
us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
134000
CY2020Q3 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-56000
CY2019Q3 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-41000
us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
6000
us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
81000
CY2020Q3 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-24000
CY2019Q3 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-12000
us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-8000
us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
24000
CY2020Q3 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-80000
CY2019Q3 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-53000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-2000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
105000
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
177000
CY2019Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-54000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
305000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
239000
CY2020Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
411000
CY2019Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
398000
us-gaap Operating Lease Cost
OperatingLeaseCost
1203000
us-gaap Operating Lease Cost
OperatingLeaseCost
988000
CY2020Q3 us-gaap Variable Lease Cost
VariableLeaseCost
93000
CY2019Q3 us-gaap Variable Lease Cost
VariableLeaseCost
83000
us-gaap Variable Lease Cost
VariableLeaseCost
282000
us-gaap Variable Lease Cost
VariableLeaseCost
178000
CY2020Q3 us-gaap Lease Cost
LeaseCost
504000
CY2019Q3 us-gaap Lease Cost
LeaseCost
481000
us-gaap Lease Cost
LeaseCost
1485000
us-gaap Lease Cost
LeaseCost
1166000
CY2020Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
412000
CY2019Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
379000
us-gaap Operating Lease Payments
OperatingLeasePayments
1201000
us-gaap Operating Lease Payments
OperatingLeasePayments
1112000
mrus Development Milestones Received
DevelopmentMilestonesReceived
3000000.0
mrus Development Milestones Received
DevelopmentMilestonesReceived
3400000
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2844000
CY2019Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2068000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6327000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5188000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Method Used
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed
Black Scholes option pricing model
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Method Used
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed
Hull White
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
11.72
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
7.45
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1236484
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1113371
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.013
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.025
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.860
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.871
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M6D
mrus Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Weighted Average Contractual Term
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsWeightedAverageContractualTerm
P10Y
us-gaap Severance Costs1
SeveranceCosts1
100000

Files In Submission

Name View Source Status
0001564590-20-051276-index-headers.html Edgar Link pending
0001564590-20-051276-index.html Edgar Link pending
0001564590-20-051276.txt Edgar Link pending
0001564590-20-051276-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
mrus-10q_20200930.htm Edgar Link pending
mrus-10q_20200930_htm.xml Edgar Link completed
mrus-20200930.xsd Edgar Link pending
mrus-20200930_cal.xml Edgar Link unprocessable
mrus-20200930_def.xml Edgar Link unprocessable
mrus-20200930_lab.xml Edgar Link unprocessable
mrus-20200930_pre.xml Edgar Link unprocessable
mrus-ex103_39.htm Edgar Link pending
mrus-ex311_9.htm Edgar Link pending
mrus-ex321_8.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending